ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals

•STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers
•Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma
•Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors

Read more
Acquisition Strengthens “Cold” Tumor Targeting Pipeline

• ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.
• Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer.

Read more